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Occupational exposure to beryllium and pro-
liferation of  industrial uses of  beryllium is
resulting in an unrecognized epidemic of
chronic beryllium disease (CBD) in the Unit-
ed States and abroad as evidenced by many
epidemiological studies over the past decade1.
Beryllium was first used in industrial appli-
cations in the 193Os in Europe, Russia and
soon thereafter in the United States (US).
Subsequently, reports of  lung and skin dis-
ease surfaced along with identification of
cases of  acute and chronic beryllium dis-
ease2,3. The exact number of  workers ex-
posed to beryllium currently or previously
in the US and internationally is unknown.
Estimates have ranged from 135,000 current
workers to 800,000 current and former work-
ers in the U.S.4. Furthermore, this is not a
problem limited to the US as beryllium ex-
posure and cases of  CBD have been report-
ed in Canada, UK, Germany, Poland, Israel
and Japan5-8. The estimates of  workers ex-
posed in other countries are quite limited;
thus the global impact of  beryllium expo-
sure is unknown.
Once largely confined to exposure in the
primary manufacture of  beryllium products
and in the nuclear weapons industry, expo-
sure to beryllium is now being discovered in
downstream industries as diverse as metal
machine shops, defense, electronics, aero-
space, aircraft manufacture, aluminum, cop-
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per and magnesium alloy manufacturing,
dental laboratories, jewelry making, and metal
recycling. As a result of  ongoing industrial
use of  beryllium internationally, cases of
chronic beryllium disease (CBD) and its pre-
cursor, beryllium sensitization, continue to
occur throughout the world in numerous
industries.
Based on the demonstration of  immunologic
response to beryllium, the blood lymphocyte
proliferation test (BeLPT), performed on
bronchoalveolar lavage cells, was the first
diagnostic method able to distinguish CBD
from sarcoidosis9 Extended for use with
blood cells in the late 1980s10, the BeLPT
became a valuable screening tool, able to
identify beryllium sensitization (BeS), an
immune response to beryllium and a precur-
sor to the lung disease along with the scar-
ring lung disease CBD.
As was hypothesized by Sterner and Eisen-
bud11, CBD is an immune-mediated hyper-
sensitivity lung disease. CD4+ T cells play a
criticai role in the immunopathogenesis of
CBD12 The diagnostic test for CBD, the be-
ryllium lymphocyte proliferation test
(BeLPT), detects the ability of blood and/
or B AL T cells to proliferate in the pres-
ence of  beryllium sulfate (BeSO/O in cul-
ture. This beryllium-induced proliferative
response is specific for CBD as neither blood
nor B AL T cells from sarcoidosis subjects
proliferate in the presence of  beryllium13.
Inhalation of  beryllium (Be) hás been asso-
ciated with two pulmonary syndromes: an
acute chemical pneumonitis and a granulo-
matous lung disease known as chronic be-
ryllium disease (CBD), or berylliosis.
• Chronic beryllium disease (CBD – Based on
our current understanding of  the patho-
physiology of  CBD as delayed-type hyper-
sensitivity, the immune response to beryl-
lium is an integral aspect to establishing
the diagnosis which is based on the pres-
ence of  ali of  the following:
1. Evidence of  an immune response to be-
ryllium by shown as a positive blood or
bronchoalveolar lavage beryllium-
-specific lymphocyte proliferation test
(BeLPT) or a positive skin patch test.
2. The presence of  non-necrotizing gran-
uloma on lung biopsy
• Beryllium sensitization (BeS): The currently
accepted definition requires: 2 abnormal
blood/BAL BeLPT, or BAL BeLPT, with
no lung pathology. The lung is the prima-
ry organ affected by CBD. Other organs
can also be affected including the extrapul-
monary lymph nodes, skin, salivary glands,
liver, spleen, kidney, bone, myocardium,
and skeletal muscle.
The main differential diagnosis of  CBD is
sarcoidosis. CBD shares many clinical and
histopathological features with pulmonary
sarcoidosis, and it is estimated that up to 6
percent of  ali patients diagnosed with sar-
coidosis actually have CBD7. The diagnosis
of  CBD and BeS requires a high degree of
clinical suspicion with the occupational his-
tory being crucial to the diagnostic evalua-
tion. Symptoms are nonspecific and include
both respiratory and constitutional com-
plaints most commonly cough, dyspnea,
wheezing and fatigue14 and may have been
present for a number of  years before patients
seek medical attention. Therefore, further
evaluation is required, beginning with the
beryllium lymphocyte proliferation test
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(BeLPT). In the late 1980s the laboratory
assay was adapted for use with peripheral
blood cells and since that time the blood and
BAL BeLPT have become the cornerstone
in the diagnosis of  CBD, allowing practition-
ers to detect disease before clinical abnor-
malities occur. The most recent and most
thorough estimate of  sensitivity and specif-
icity was published by Stange et all based on
19,396 BeLPT results. The group determined
that the BeLPT hás sensitivity for CBD of
68.3% and a specificity of 96.9%15. Once a
patient is determined to be sensitized by the
BeLPT the clinician still needs to determine
whether or not CBD is present. The main
test used for this purpose is bronchoscopy
to obtain lung biopsy. Pulmonary function
testing is non-specific featuring a range of
abnormalities including obstruction, restric-
tion, a mixed process, and/or a reduced
DLCO, with obstruction being the most
common abnormality. Normal pulmonary
function testing is also common especially
in early disease16-17. Likewise, radiologic test-
ing including chest x-ray and high resolution
CT will miss a significant number of  cases
of  beryllium disease. It was shown that the
sensitivity of  the chest radiograph for biopsy-
-proven chronic beryllium disease was about
45%, compared with about 89% for HRCT18-
-19. As sensitivity and specificity of  both ra-
diologic and physiologic studies is less than
that of  bronchoscopy for the detection of
chronic beryllium disease one should con-
sider performing a bronchoscopy on sensi-
tized individuals who do not have contrain-
dications for the procedure in order to
defmitively define their disease status and
guide subsequent management. The bron-
choscopy should include both bronchoalve-
olar lavage and transbronchial biopsy when
possible. The biopsies are performed to es-
tablish the presence of  granulomas and/or
mononuclear interstitial infiltrates consistent
with chronic beryllium. A B AL is also ob-
tained to determine if  a lymphocytic alveoli-
tis is present and whether lung cells respond
to beryllium in a BAL BeLPT. When sensi-
tized patients cannot undergo a bronchos-
copy a probable diagnosis of  CBD may still
be reached if  a high resolution CT shows
typical abnormalities. Preliminary results with
adding neopterin measurements to the pe-
ripheral blood BeLPT show an improved
ability to differentiate CBD from BeS20.
ELISPOT analysis demonstrate that patients
with CBD have a significantly elevated
number of  IFN-y-producing and IL-2-
-producing beryllium-specific CD4+ T cells
in blood compared with both BeS and nor-
mal control subjects21. Analysis of induced
sputum for lymphocyte percentage and
CD4:CD8 ratio correlates well to those re-
covered by BAL and can effectively and non-
invasively identify CD4+ inflammation in
order to distinguish between sarcoidosis and
other non-granulomatous interstitial lung
diseases22.
In conclusion BAL is a well-defined tool in
the Diagnostic Algorithm for CBD and re-
search of  immunopathogenesis of  disease.
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